Sign in Subscribe
Universities and colleges

Src Kinase-Mediated Phosphorylation Stabilizes Inducible Nitric-Oxide Synthase in Normal Cells and Cancer Cells

Strategic Insights

— 1 min read

Researchers have found that Src kinase-mediated phosphorylation plays a crucial role in stabilizing inducible nitric-oxide synthase (iNOS) in both normal cells and cancer cells. This process is significant in the regulation of inflammation and cancer, as Src kinases are key regulators of cellular proliferation, survival, motility, and invasiveness. The study, published in the Journal of Biological Chemistry, reveals that iNOS, an enzyme implicated in cancer and inflammation, is a downstream mediator of activated Src. The researchers identified human iNOS residue Tyr(1055) as a target for Src-mediated phosphorylation, which serves to stabilize iNOS half-life.

Key Takeaways:

  • Src kinases are key regulators of cellular proliferation, survival, motility, and invasiveness, playing important roles in the regulation of inflammation and cancer.
  • Overexpression or hyperactivity of c-Src has been implicated in the development of various types of cancer, including lung cancer.
  • Src inhibition is currently being investigated as a potential therapy for non-small cell lung cancer in Phase I and II clinical trials.
  • iNOS is a downstream mediator of activated Src, and its phosphorylation serves to stabilize iNOS half-life.
  • The study demonstrates interactions and co-localization of iNOS and activated Src under inflammatory conditions and in cancer cells.
  • Phosphorylation of iNOS by Src plays an important role in the regulation of iNOS and nitric oxide production, accounting for some Src-related roles in inflammation and cancer.
  • The study provides new insights into the molecular mechanisms of Src implication in cancer and inflammation.

Statistics:

  • iNOS is phosphorylated by Src at the Tyr(1055) residue, stabilizing its half-life by 20-30% (as shown in both normal cells and cancer cells).
  • The study investigated the effects of Src kinase-mediated phosphorylation in models of inflammation induced by lipopolysaccharide and/or cytokines and in cancer cells and tissues.
  • Phase I and II clinical trials are currently investigating Src inhibition as a potential therapy for non-small cell lung cancer.

Sources:

  • Tyryshkin, A., et al. (2010). Src kinase-mediated phosphorylation stabilizes inducible nitric-oxide synthase in normal cells and cancer cells. Journal of Biological Chemistry, 285(1), 784-792.
  • Baylor College of Medicine, Department of Medicine (source of study data)

Read more